These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 17541428

  • 21. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
    Ishii Y, Pirkmaier A, Alvarez JV, Frank DA, Keselman I, Logothetis D, Mandeli J, O'Connell MJ, Waxman S, Germain D.
    J Natl Cancer Inst; 2006 Sep 06; 98(17):1238-47. PubMed ID: 16954476
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
    Fujita T, Doihara H, Washio K, Ino H, Murakami M, Naito M, Shimizu N.
    Anticancer Drugs; 2007 Jul 06; 18(6):677-86. PubMed ID: 17762396
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
    Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, Al-Daccak R, Aoudjit F.
    Mol Cancer Res; 2008 Jan 06; 6(1):42-52. PubMed ID: 18234961
    [Abstract] [Full Text] [Related]

  • 29. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
    Dai Y, Chen S, Kramer LB, Funk VL, Dent P, Grant S.
    Clin Cancer Res; 2008 Jan 15; 14(2):549-58. PubMed ID: 18223231
    [Abstract] [Full Text] [Related]

  • 30. Drug discovery and assay development in the ubiquitin-proteasome system.
    Berkers CR, Ovaa H.
    Biochem Soc Trans; 2010 Feb 15; 38(Pt 1):14-20. PubMed ID: 20074028
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R.
    Cancer Chemother Pharmacol; 2008 Apr 15; 61(4):549-58. PubMed ID: 17522864
    [Abstract] [Full Text] [Related]

  • 33. The role of proteasome in malignant diseases.
    Moran E, Nencioni A.
    J BUON; 2007 Sep 15; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
    Basler M, Lauer C, Beck U, Groettrup M.
    J Immunol; 2009 Nov 15; 183(10):6145-50. PubMed ID: 19841190
    [Abstract] [Full Text] [Related]

  • 36. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
    Hutter G, Rieken M, Pastore A, Weigert O, Zimmermann Y, Weinkauf M, Hiddemann W, Dreyling M.
    Ann Hematol; 2012 Jun 15; 91(6):847-56. PubMed ID: 22231280
    [Abstract] [Full Text] [Related]

  • 37. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
    Lyu MA, Pham LV, Sung B, Tamayo AT, Ahn KS, Hittelman WN, Cheung LH, Marks JW, Cho MJ, Ford RJ, Aggarwal BB, Rosenblum MG.
    Biochem Pharmacol; 2012 Aug 15; 84(4):451-8. PubMed ID: 22687624
    [Abstract] [Full Text] [Related]

  • 38. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
    Chu S, Alexiadis M, Fuller PJ.
    Reprod Sci; 2009 Apr 15; 16(4):397-407. PubMed ID: 19087975
    [Abstract] [Full Text] [Related]

  • 39. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib.
    Chen S, Blank JL, Peters T, Liu XJ, Rappoli DM, Pickard MD, Menon S, Yu J, Driscoll DL, Lingaraj T, Burkhardt AL, Chen W, Garcia K, Sappal DS, Gray J, Hales P, Leroy PJ, Ringeling J, Rabino C, Spelman JJ, Morgenstern JP, Lightcap ES.
    Cancer Res; 2010 Jun 01; 70(11):4318-26. PubMed ID: 20460535
    [Abstract] [Full Text] [Related]

  • 40. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L.
    Clin Cancer Res; 2007 Oct 01; 13(19):5942-51. PubMed ID: 17908991
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.